Pharmaceuticals
10 Pfizer business development leaders
These ten Pfizer business development leaders hold director, senior director and executive director roles in worldwide business development, R&D business development, licensing, search and evaluation and corporate development at Pfizer. A reader can learn how business development leaders work at Pfizer from people who have held the role.
Professionals to explore
01—10Anne-Marie Mueller
LinkedInExperience: Senior Director, R&D Business Development, Oncology and Diagnostics · Pfizer
Senior Director, R&D Business Development, Oncology and Diagnostics at Pfizer since November 2023, after 13 years as Director, Worldwide R&D Business Development (2010–2023); her profile describes leading, negotiating and managing all types of technology licensing. She earlier spent 16 years as Senior Director, Office of Technology Management at the Salk Institute.
Hilde Stubdal
LinkedInExperience: Executive Director, Worldwide Business Development, Oncology Search & Evaluation Lead · Pfizer
Executive Director, Worldwide Business Development, Oncology Search & Evaluation Lead at Pfizer since January 2019, after a year as Executive Director, External Science, Immuno-oncology Lead. She earlier worked in corporate development, licensing and M&A at Onyx Pharmaceuticals (2008–2013) and was Principal at BioAssess LLC, a business development consulting firm (2013–2018).
Jackeline Ferrigno
LinkedInExperience: Director Of Business Development & Licensing · Pfizer
Director of Business Development & Licensing at Pfizer since March 2014, after serving as Global Director, Marketing Research at Pfizer (2011–2014). Her profile describes experience across business development, M&A, strategic planning, finance and marketing, including licensing, acquisitions, divestitures, due diligence and negotiations.
Kelly Callahan
LinkedInExperience: Director, R&D Business Development (Oncology) · Pfizer
Director, R&D Business Development (Oncology) at Pfizer since May 2024, in the research department at director level, after a short stint as Associate Director in the same group. Before Pfizer, Kelly Callahan worked in corporate development at Seagen from 2018 to 2023 as Manager, Senior Manager and then Associate Director, Corporate Development.
Leslie Coney
LinkedInExperience: Senior Director Business Development · Pfizer
Senior Director Business Development at Pfizer since October 2017 and Director, Worldwide Business Development at Pfizer since February 2011. Her profile describes closing research collaborations, in-licensing, out-licensing, co-development and co-commercialization agreements. She has also held business development, corporate development and technology transfer roles at Biogen and Biogen Idec.
Marion Fitzpatrick
LinkedInExperience: Senior Director, Portfolio Leader Outlicensing, Business Development · Pfizer
Senior Director, Portfolio Leader Outlicensing, Business Development at Pfizer since August 2010; her profile says she leads teams preparing due diligence data rooms for outlicensing deals and, once a deal closes, leads the tech transfers in line with the legal agreement. She was earlier a Director (2003–2010) and Associate Director (2001–2003) at Pfizer.
Michael Flakus
LinkedInExperience: Senior Director, Worldwide Business Development · Pfizer
Senior Director, Worldwide Business Development at Pfizer since January 2018, a role his profile lists in general management at director level. He has also held the title Director, Worldwide Business Development at Pfizer since 2000, and was a Scientist at Pfizer from 1995 to 2000.
Sumant Sherma
LinkedInExperience: Senior Director of Business Development · Pfizer
Senior Director of Business Development at Pfizer since June 2013, based in London; the profile describes global responsibility for revenue goals, drafting term sheets and license agreements, financial modeling and pursuing M&A opportunities. Before Pfizer, Sumant Sherma was a BD Manager at GSK (2010–2013).
Susan Dunne
LinkedInExperience: Senior Director, Worldwide Business Development · Pfizer
Senior Director, Worldwide Business Development at Pfizer since August 2019; her profile says she leads enterprise-wide setup, planning and execution of multi-billion-dollar deal integrations. She was earlier Director, International Treasury (2014–2019) and Global Financial Solutions Lead (2008–2014) at Pfizer.
Zeena Advani
LinkedInExperience: Director (Vaccines & Internal Medicine), Corporate Development · Pfizer
Director (Vaccines & Internal Medicine), Corporate Development at Pfizer since April 2022, after serving as Manager and Senior Manager in Pfizer corporate development from 2018. Her profile describes identifying, structuring and negotiating transactions including public and private acquisitions and asset divestitures. She was earlier a private equity associate at Apax.
Choose the right perspective
Match the person's scope to your question, since search and evaluation, in-licensing, out-licensing, corporate development transactions and deal integration involve different work. Check which therapeutic area and deal type the person's role covers, since that shapes what they can speak to.
Questions to take into the conversation
- 01How does a large pharmaceutical company decide which external assets to license or acquire?
- 02How are search and evaluation teams organized by therapeutic area?
- 03How does a business development team manage integration after a large acquisition closes?
Reaching Pfizer business development leaders
How can I contact one of these Pfizer business development leaders?
Pick one of the 10 people on this page and choose "Book a paid call", or describe your project to find others. You offer a fee for a 15-minute call or a written answer, Instant Expert finds the person's work email and sends the invitation, and they decide whether to accept. The list covers 1 company: Pfizer, based on profile data retrieved on October 9, 2026. Being listed here doesn't mean someone has agreed to take calls.
How much does it cost to reach Pfizer business development leaders?
You choose the offer, starting at $5 per person. It includes Instant Expert's 20% fee, so an offer that pays the person $100 costs you $125. You're charged only when the person books the call or sends the answer.
What if they don't reply?
You pay nothing. Instant Expert sends follow-up reminders, and if the person hasn't booked or answered within 7 days, the request expires and any hold on your card is released. You can invite several of the 10 people on this list at once and cap your total spend, so you pay only for the ones who accept.
Can an AI agent ask one of these Pfizer business development leaders a question?
Yes. An agent with a USDC wallet on Base can ask one question without an Instant Expert account. It names the person, for example by the LinkedIn URL on this page, and pays per ask over x402 (HTTP 402). The person answers in writing or by voice note, and if nobody answers within 7 days, the payment goes back to the wallet automatically. x402 docs
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot and may describe past or present roles. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.
Request a correction or removal